Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at William Blair

Equities researchers at William Blair started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Wednesday. The brokerage set an “outperform” rating on the stock.

A number of other brokerages have also issued reports on JSPR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Piper Sandler assumed coverage on shares of Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.33.

Jasper Therapeutics Price Performance

JSPR stock traded up $0.01 on Wednesday, reaching $0.51. The company’s stock had a trading volume of 21,408 shares, compared to its average volume of 819,857. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $2.69. The company has a market capitalization of $16.81 million, a P/E ratio of -0.32 and a beta of 3.16. The firm has a fifty day moving average of $0.67 and a two-hundred day moving average of $0.70.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities analysts expect that Jasper Therapeutics will post -1.14 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.